Latest Insider Transactions at Oncology Institute, Inc. (TOI)
This section provides a real-time view of insider transactions for Oncology Institute, Inc. (TOI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Oncology Institute, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Oncology Institute, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 14
2023
|
Brad Hively Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,117
-3.74%
|
$54,234
$2.39 P/Share
|
|
Nov 13
2023
|
Brad Hively Director |
SELL
Open market or private sale
|
Direct |
47,000
-6.09%
|
$94,000
$2.52 P/Share
|
|
Nov 13
2023
|
Brad Hively Director |
BUY
Exercise of conversion of derivative security
|
Direct |
47,000
+5.74%
|
$0
$0.85 P/Share
|
|
May 23
2023
|
Mihir Shah Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,442
-0.76%
|
$0
$0.43 P/Share
|
|
Mar 17
2023
|
Mohit Kaushal Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,685
+31.71%
|
-
|
|
Mar 17
2023
|
Mihir Shah Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
176,191
+43.71%
|
-
|
|
Mar 17
2023
|
Richard A Barasch Director |
BUY
Open market or private purchase
|
Direct |
50,000
+2.55%
|
$0
$0.55 P/Share
|
|
Mar 17
2023
|
Yale Podnos Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,219
+26.86%
|
-
|
|
Mar 17
2023
|
Matthew P Miller Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
67,667
+21.78%
|
-
|
|
Mar 17
2023
|
Maeve O'Meara Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,404
+21.72%
|
-
|
|
Mar 17
2023
|
Daniel Virnich Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
114,944
+13.47%
|
-
|
|
Mar 17
2023
|
Ravi Yang Sarin Director |
BUY
Grant, award, or other acquisition
|
Direct |
29,528
+28.13%
|
-
|
|
Mar 17
2023
|
Karen Marie Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,685
+23.75%
|
-
|
|
Mar 17
2023
|
Mark L Pacala Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,562
+6.91%
|
-
|
|
Mar 17
2023
|
Anne Mc George Director |
BUY
Grant, award, or other acquisition
|
Direct |
26,247
+26.89%
|
-
|
|
Mar 17
2023
|
Brad Hively Director |
BUY
Grant, award, or other acquisition
|
Direct |
168,512
+18.88%
|
-
|
|
Dec 16
2022
|
Matthew P Miller Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
73,684
+29.59%
|
$0
$0.95 P/Share
|
|
Dec 07
2022
|
Daniel Virnich Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
350,000
+24.99%
|
$0
$0.86 P/Share
|
|
Nov 17
2022
|
Richard A Barasch Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,708
+12.12%
|
-
|
|
Nov 17
2022
|
Brad Hively Director |
BUY
Grant, award, or other acquisition
|
Direct |
103,469
+15.7%
|
-
|
|
Nov 17
2022
|
Karen Marie Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,708
+34.3%
|
-
|
|
Nov 17
2022
|
Mohit Kaushal Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,708
+32.01%
|
-
|
|
Nov 17
2022
|
Gabriel Ling Director |
BUY
Grant, award, or other acquisition
|
Direct |
29,057
+50.0%
|
-
|
|
Nov 17
2022
|
Anne Mc George Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,708
+33.49%
|
-
|
|
Nov 17
2022
|
Matthew P Miller Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,607
+18.85%
|
-
|
|
Nov 17
2022
|
Maeve O'Meara Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,708
+34.72%
|
-
|
|
Nov 17
2022
|
Mark L Pacala Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,217
+15.07%
|
-
|
|
Nov 17
2022
|
Yale Podnos Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,164
+19.83%
|
-
|
|
Nov 17
2022
|
Ravi Yang Sarin Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,708
+33.1%
|
-
|
|
Nov 17
2022
|
Mihir Shah Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,602
+26.83%
|
-
|
|
Nov 17
2022
|
Diona Simoneit Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,387
+20.74%
|
-
|
|
Nov 17
2022
|
Daniel Virnich Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,101
+12.78%
|
-
|
|
Nov 15
2022
|
Brad Hively Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,718
-2.1%
|
$19,436
$2.03 P/Share
|
|
Nov 15
2022
|
Matthew P Miller Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
577
-0.73%
|
$1,154
$2.03 P/Share
|
|
Nov 15
2022
|
Yale Podnos Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
199
-0.46%
|
$398
$2.03 P/Share
|
|
Nov 15
2022
|
Diona Simoneit Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
190
-0.64%
|
$380
$2.03 P/Share
|
|
Nov 15
2022
|
Daniel Virnich Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,767
-1.59%
|
$7,534
$2.03 P/Share
|
|
Nov 14
2022
|
Mohit Kaushal Director |
SELL
Open market or private sale
|
Direct |
15,994
-38.51%
|
$31,988
$2.13 P/Share
|
|
Nov 11
2022
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
365,321
-2.66%
|
$730,642
$2.33 P/Share
|
|
Nov 10
2022
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
61,281
-0.44%
|
$122,562
$2.98 P/Share
|
|
Nov 09
2022
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
80,000
-0.58%
|
$240,000
$3.09 P/Share
|
|
Nov 08
2022
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
27,000
-0.19%
|
$81,000
$3.24 P/Share
|
|
Nov 07
2022
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
19,167
-0.14%
|
$57,501
$3.28 P/Share
|
|
Nov 04
2022
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
50,200
-0.36%
|
$150,600
$3.39 P/Share
|
|
Nov 03
2022
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
45,500
-0.32%
|
$136,500
$3.58 P/Share
|
|
Nov 02
2022
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
58,500
-0.42%
|
$175,500
$3.94 P/Share
|
|
Nov 01
2022
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
50,272
-0.36%
|
$201,088
$4.26 P/Share
|
|
Oct 31
2022
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
41,855
-0.3%
|
$167,420
$4.69 P/Share
|
|
Oct 28
2022
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
52,091
-0.37%
|
$208,364
$4.84 P/Share
|
|
Oct 27
2022
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
35,000
-0.25%
|
$175,000
$5.09 P/Share
|